UPDATE: Seven Complete Responses in a 19-Patient Cohort of 67Cu-SAR-bisPSMA Trial for mCRPC

/in , , , /by

A small but encouraging clinical dataset suggests that 67Cu-SAR-bisPSMA may produce substantial anti-tumour activity in patients with metastatic castration-resistant prostate cancer (mCRPC) who have exhausted multiple treatment options. The findings come from the SECuRE clinical trial, in which 19 participants received treatment with 67Cu-SAR-bisPSMA at an 8 GBq dose. Despite the advanced disease setting, treatment […]

Read more

B7-H3: A Continuum-Wide, AR-Repressed Anchor for Combinatorial Prostate Cancer Therapy

/in /by

A landmark 2026 study in Clinical Cancer Research reframes surface-target therapy in advanced prostate cancer by placing B7-H3 (CD276) at the center of a continuum-wide strategy. Integrating the JHU-PANORAMA single-cell atlas (~1M cells, 213 patients) with patient-derived xenografts, metastatic rapid-autopsy tissues, and mechanistic cell-line work, the authors show that B7-H3 is the most uniformly expressed […]

Read more

Viagra Might Help To Reduce Metastasis

/in , /by

A recent study is drawing attention for a surprising reason: sildenafil, the active ingredient in Viagra, may do more than treat erectile dysfunction. Researchers reported evidence that it could also make it harder for cancer cells to spread, by interfering with the cells’ ability to access cholesterol, which appears to be important for metastasis. The […]

Read more

Blocking BCL-XL Increases ADC Effectiveness

/in , /by

UCLA researchers have reported a promising way to improve antibody-drug conjugates, or ADCs, in metastatic castration-resistant prostate cancer, a disease that remains difficult to control once it stops responding to hormone therapy. Their work suggests that pairing ADCs with a drug that blocks BCL-XL can make prostate cancer cells more vulnerable, leading to greater cell […]

Read more

Pluvicto Moves Into First-Line Metastatic Prostate Cancer, Marking Shift Toward Earlier Radioligand Therapy

/in , , , /by

A new regulatory approval is reshaping the treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC), bringing radioligand therapy into much earlier stages of disease. Pluvicto (lutetium Lu-177 vipivotide tetraxetan aka 177Lu-PSMA-617), a therapy targeting prostate-specific membrane antigen (PSMA), can now be used in combination with standard androgen deprivation therapy and androgen receptor pathway inhibitors in […]

Read more

Newsletter 31/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Another heatwave, another newsletter (but the two are not correlated!). Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical Research Phase 2 Trial […]

Read more